Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Bennett

Showing results (81-90 of 164) with videos related to

Pageof 17
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|February 12, 2020
Decoding Bone Marrow Fibrosis in Myelodysplastic SyndromesMegan Melody, Najla Al Ali, Ling Zhang, et al.
Leukemia Research|September 6, 2011
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature reviewMichael J Rauh, Fazlur Rahman, David Good, et al.
Leukemia Research|December 7, 2007
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based surveyDavid P Steensma, Kathleen V Heptinstall, Victor M Johnson, et al.
Blood Cancer Journal|March 3, 2025
Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entityIsolde Summerer, Wencke Walter, Manja Meggendorfer, et al.
Leukemia Research|July 26, 2011
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literatureRahel A Mathew, John M Bennett, Jane Jijun Liu, et al.
Cancer|July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Blood|August 19, 2010
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999Larry D Cripe, Hajime Uno, Elisabeth M Paietta, et al.
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Blood|March 27, 2004
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemiasElisabeth Paietta, Adolfo A Ferrando, Donna Neuberg, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
Pageof 17

Showing results (81-90 of 164) with videos related to

Sort By:
Pageof 17
Clinical Lymphoma, Myeloma & Leukemia|February 12, 2020
Decoding Bone Marrow Fibrosis in Myelodysplastic SyndromesMegan Melody, Najla Al Ali, Ling Zhang, et al.
Leukemia Research|September 6, 2011
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature reviewMichael J Rauh, Fazlur Rahman, David Good, et al.
Leukemia Research|December 7, 2007
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based surveyDavid P Steensma, Kathleen V Heptinstall, Victor M Johnson, et al.
Blood Cancer Journal|March 3, 2025
Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entityIsolde Summerer, Wencke Walter, Manja Meggendorfer, et al.
Leukemia Research|July 26, 2011
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literatureRahel A Mathew, John M Bennett, Jane Jijun Liu, et al.
Cancer|July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Blood|August 19, 2010
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999Larry D Cripe, Hajime Uno, Elisabeth M Paietta, et al.
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Blood|March 27, 2004
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemiasElisabeth Paietta, Adolfo A Ferrando, Donna Neuberg, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
Pageof 17